Valneva SE
3.2420
11-三月-25 11:29:57
15 分钟延时
股票
-0.0500
-1.52%
今日范围
3.2080 - 3.3000
ISIN
FR0004056851
来源
Cboe
-
Valneva Vaccinates First Participant in Pediatric Trial of Single-Shot Chikungunya Vaccine
10 1月 2024 00:00:00 条件 Nasdaq GlobeNewswire
-
VALNEVA - Declaration of shares and voting rights: December 31, 2023
05 1月 2024 01:30:00 条件 Nasdaq GlobeNewswire
-
Valneva to Conduct Investor Meetings during the J.P. Morgan Healthcare Conference and Oddo BHF Forum
04 1月 2024 10:45:00 条件 Nasdaq GlobeNewswire
-
Valneva Provides Updated 2023 Financial Guidance
29 12月 2023 15:30:00 条件 Nasdaq GlobeNewswire
-
Valneva Shareholders Approve EGM Resolutions Including the Transition to a Board of Directors
20 12月 2023 10:45:00 条件 Nasdaq GlobeNewswire
-
VALNEVA Declaration of shares and voting rights - November 30, 2023
06 12月 2023 01:30:00 条件 Nasdaq GlobeNewswire
-
04 12月 2023 15:20:00 条件 Nasdaq GlobeNewswire
-
04 12月 2023 00:00:00 条件 Nasdaq GlobeNewswire
-
27 11月 2023 00:00:00 条件 Nasdaq GlobeNewswire
-
15 11月 2023 00:30:00 条件 Nasdaq GlobeNewswire
-
Valneva Announces U.S. FDA Approval of World’s First Chikungunya Vaccine, IXCHIQ®
10 11月 2023 00:00:00 条件 Nasdaq GlobeNewswire
-
Valneva Reports Nine-Month 2023 Financial Results and Provides Corporate Updates
09 11月 2023 00:00:00 条件 Nasdaq GlobeNewswire
-
Valneva to Present and Hold Investor Meetings at the Jefferies London Healthcare Conference
07 11月 2023 00:00:00 条件 Nasdaq GlobeNewswire
-
VALNEVA Declaration of shares and voting rights: October 31, 2023
06 11月 2023 01:30:00 条件 Nasdaq GlobeNewswire
-
25 10月 2023 11:15:00 条件 Nasdaq GlobeNewswire
-
Valneva to Present on Chikungunya at Several Leading Scientific Conferences
11 10月 2023 10:45:00 条件 Nasdaq GlobeNewswire
-
VALNEVA - Declaration of shares and voting rights: September 30, 2023
05 10月 2023 01:30:00 条件 Nasdaq GlobeNewswire
-
25 9月 2023 00:00:00 条件 Nasdaq GlobeNewswire
-
Valneva Reports Half Year 2023 Financial Results and Provides Corporate Updates
21 9月 2023 00:00:00 条件 Nasdaq GlobeNewswire
-
07 9月 2023 00:00:00 条件 Nasdaq GlobeNewswire